Display options
Cite
Bergamin LS, Capece M, Salaro E, et al. Role of the P2X7 receptor in . Oncotarget. 2019;10(47):4840-4856doi: 10.18632/oncotarget.27106.
Bergamin, L. S., Capece, M., Salaro, E., Sarti, A. C., Falzoni, S., Pereira, M. S. L., De Bastiani, M. A., Scholl, J. N., Battastini, A. M. O., & Di Virgilio, F. (2019). Role of the P2X7 receptor in . Oncotarget, 10(47), 4840-4856. https://doi.org/10.18632/oncotarget.27106
Bergamin, Letícia Scussel, et al. "Role of the P2X7 receptor in ." Oncotarget vol. 10,47 (2019): 4840-4856. doi: https://doi.org/10.18632/oncotarget.27106
Bergamin LS, Capece M, Salaro E, Sarti AC, Falzoni S, Pereira MSL, De Bastiani MA, Scholl JN, Battastini AMO, Di Virgilio F. Role of the P2X7 receptor in . Oncotarget. 2019 Aug 06;10(47):4840-4856. doi: 10.18632/oncotarget.27106. eCollection 2019 Aug 06. PMID: 31448051; PMCID: PMC6690673.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2019 Aug 06;10(47):4840-4856. doi: 10.18632/oncotarget.27106. eCollection 2019 Aug 06.

Role of the P2X7 receptor in .

Oncotarget

Letícia Scussel Bergamin, Marina Capece, Erica Salaro, Alba Clara Sarti, Simonetta Falzoni, Mery Stéfani Leivas Pereira, Marco Antônio De Bastiani, Juliete Nathali Scholl, Ana Maria O Battastini, Francesco Di Virgilio

Affiliations

  1. Graduate Program in Biological Sciences/Biochemistry, Institute of Basic Health Sciences and Department of Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
  2. CAPES Foundation, Ministry of Education of Brazil, Brasília DF, Brazil.
  3. Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Ferrara, Italy.

PMID: 31448051 PMCID: PMC6690673 DOI: 10.18632/oncotarget.27106

Abstract

Human glioblastoma cells are strikingly refractory to ATP-stimulated, P2X7 receptor (P2X7R)-mediated cytotoxicity. To elucidate the mechanistic basis of this feature, we investigated P2X7R-dependent responses in wild type and P2X7R-transfected U138 cells. Mouse GL261 glioma cells were used as an additional control. Here, we report that wild type U138 glioma cells expressed the P2X7R to very low level. Contrary to human U138 cells, mouse GL261 cells showed strong P2X7R expression and P2X7R-dependent responses. Transfection of wild type

Keywords: P2X7R; cancer; extracellular ATP; glioma; purinergic signaling

Conflict of interest statement

CONFLICTS OF INTEREST FDV is a member of the Scientifc Advisory Board (SAB) of Biosceptre Ltd, a UK-based Biotech Company involved in the development of P2X7R-targeted antibodies. Other authors declar

References

  1. Br J Haematol. 1999 Apr;105(1):181-9 - PubMed
  2. J Biol Chem. 2001 Apr 6;276(14):11135-42 - PubMed
  3. Blood. 2001 Feb 1;97(3):587-600 - PubMed
  4. Pharmacol Rev. 2001 Mar;53(1):107-18 - PubMed
  5. J Neurosurg. 2001 Aug;95(2):190-8 - PubMed
  6. Methods. 2001 Dec;25(4):402-8 - PubMed
  7. Lancet. 2002 Mar 30;359(9312):1114-9 - PubMed
  8. Physiol Rev. 2002 Oct;82(4):1013-67 - PubMed
  9. Curr Mol Med. 2003 Feb;3(1):73-84 - PubMed
  10. FEBS Lett. 2003 Mar 13;538(1-3):159-62 - PubMed
  11. Glia. 2003 Sep;43(3):218-03 - PubMed
  12. J Neurooncol. 2004 Nov;70(2):217-28 - PubMed
  13. J Neurooncol. 2005 Jan;71(2):135-40 - PubMed
  14. Mol Biol Cell. 2005 Jul;16(7):3260-72 - PubMed
  15. J Immunol. 2005 Jul 1;175(1):82-9 - PubMed
  16. BMC Cancer. 2006 Sep 23;6:226 - PubMed
  17. J Cancer Res Clin Oncol. 2008 Mar;134(3):365-72 - PubMed
  18. Cancer Lett. 2008 Feb 18;260(1-2):79-87 - PubMed
  19. PLoS One. 2008 Jul 09;3(7):e2599 - PubMed
  20. N Engl J Med. 2008 Jul 31;359(5):492-507 - PubMed
  21. Mol Neurobiol. 2009 Jun;39(3):190-208 - PubMed
  22. J Cell Biochem. 2010 Apr 1;109(5):983-91 - PubMed
  23. Cancer Cell. 2010 Jan 19;17(1):98-110 - PubMed
  24. J Neuropathol Exp Neurol. 2011 Jan;70(1):13-22 - PubMed
  25. Expert Opin Investig Drugs. 2011 Jul;20(7):875-80 - PubMed
  26. Cancer Res. 2012 Jun 15;72(12):2957-69 - PubMed
  27. Cancer Res. 2012 Nov 1;72(21):5441-7 - PubMed
  28. J Biomed Biotechnol. 2012;2012:959848 - PubMed
  29. Int J Biochem Cell Biol. 2013 Jun;45(6):1109-20 - PubMed
  30. Front Pharmacol. 2013 May 07;4:55 - PubMed
  31. Nat Genet. 2013 Oct;45(10):1113-20 - PubMed
  32. Cell. 2013 Oct 10;155(2):462-77 - PubMed
  33. Cell Death Dis. 2014 Mar 20;5:e1135 - PubMed
  34. PLoS One. 2014 Sep 16;9(9):e107224 - PubMed
  35. Biochim Biophys Acta. 2015 Jan;1852(1):120-30 - PubMed
  36. J Cell Biochem. 2015 May;116(5):721-9 - PubMed
  37. Oncogene. 2015 Oct 8;34(41):5240-51 - PubMed
  38. Oxid Med Cell Longev. 2015;2015:172493 - PubMed
  39. Purinergic Signal. 2015 Sep;11(3):331-46 - PubMed
  40. Pharmacol Res Perspect. 2015 Mar;3(2):e00123 - PubMed
  41. Int J Biochem Cell Biol. 2015 Nov;68:92-100 - PubMed
  42. Cell. 2016 Jan 28;164(3):550-63 - PubMed
  43. PLoS Genet. 2016 May 12;12(5):e1006000 - PubMed
  44. Oncogene. 2017 Jan 19;36(3):293-303 - PubMed
  45. Cancer Lett. 2017 Aug 28;402:93-99 - PubMed
  46. Immunity. 2017 Jul 18;47(1):15-31 - PubMed
  47. J Mol Cell Biol. 2018 Jun 1;10(3):229-242 - PubMed
  48. Trends Cell Biol. 2018 May;28(5):392-404 - PubMed
  49. Biomed Res Int. 2018 Jan 9;2018:8591397 - PubMed
  50. Nat Rev Cancer. 2018 Oct;18(10):601-618 - PubMed
  51. Oncogene. 2019 Jan;38(2):194-208 - PubMed
  52. Oncogene. 2019 May;38(19):3636-3650 - PubMed
  53. J Neuroimmunol. 2019 Jul 15;332:138-146 - PubMed
  54. Pharmacol Ther. 1994;64(3):445-75 - PubMed
  55. J Clin Invest. 1995 Mar;95(3):1207-16 - PubMed
  56. J Biol Chem. 1997 Feb 28;272(9):5482-6 - PubMed
  57. Anal Biochem. 1976 May 7;72:248-54 - PubMed

Publication Types